Unique microbial communities persist in individual cystic fibrosis patients throughout a clinical exacerbation

被引:107
|
作者
Price, Katherine E. [1 ]
Hampton, Thomas H. [1 ]
Gifford, Alex H. [2 ]
Dolben, Emily L. [1 ]
Hogan, Deborah A. [1 ]
Morrison, Hilary G. [3 ]
Sogin, Mitchell L. [3 ]
O'Toole, George A. [1 ]
机构
[1] Geisel Sch Med Dartmouth, Dept Microbiol & Immunol, Hanover, NH 03755 USA
[2] Dartmouth Hitchcock Med Ctr, Sect Pulm & Crit Care Med, Lebanon, NH 03756 USA
[3] Marine Biol Lab, Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Woods Hole, MA 02543 USA
来源
MICROBIOME | 2013年 / 1卷
基金
美国国家卫生研究院;
关键词
Cystic fibrosis; Cystic fibrosis pulmonary exacerbation; Microbiome; Sputum; Pseudomonas aeruginosa; STAPHYLOCOCCUS-AUREUS; PATHOGENESIS; DIVERSITY; DISEASE;
D O I
10.1186/2049-2618-1-27
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Cystic fibrosis (CF) is caused by inherited mutations in the cystic fibrosis transmembrane conductance regulator gene and results in a lung environment that is highly conducive to polymicrobial infection. Over a lifetime, decreasing bacterial diversity and the presence of Pseudomonas aeruginosa in the lung are correlated with worsening lung disease. However, to date, no change in community diversity, overall microbial load or individual microbes has been shown to correlate with the onset of an acute exacerbation in CF patients. We followed 17 adult CF patients throughout the course of clinical exacerbation, treatment and recovery, using deep sequencing and quantitative PCR to characterize spontaneously expectorated sputum samples Results: We identified approximately 170 bacterial genera, 12 of which accounted for over 90% of the total bacterial load across all patient samples. Genera abundant in any single patient sample tended to be detectable in most samples. We found that clinical stages could not be distinguished by absolute Pseudomonas aeruginosa load, absolute total bacterial load or the relative abundance of any individual genus detected, or community diversity. Instead, we found that the microbial structure of each patient's sputum microbiome was distinct and resilient to exacerbation and antibiotic treatment. Conclusion: Consistent with previously reported sputum microbiome studies we found that total and relative abundance of genera at the population level were remarkably stable for individual patients regardless of clinical status. Patient-by-patient analysis of diversity and relative abundance of each individual genus revealed a complex microbial landscape and highlighted the difficulty of identifying a universal microbial signature of exacerbation. Overall, at the genus level, we find no evidence of a microbial signature of clinical stage.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Pediatric hospital in the home: clinical outcomes for treatment of a cystic fibrosis respiratory exacerbation
    Hough, Judith
    Christensen, Hannah
    PHYSIOTHERAPY THEORY AND PRACTICE, 2021, 37 (12) : 1298 - 1305
  • [32] LONGITUDINAL DYNAMICS OF CYSTIC FIBROSIS AIRWAYS' MICROBIOTA DURING CLINICAL STABILITY AND EXACERBATION
    Boutin, S.
    Stahl, M.
    Graeber, S. Y.
    Dittrich, S.
    Mall, M.
    Dalpke, A.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 312 - 313
  • [33] A Randomized Clinical Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment
    Goss, Christopher H.
    Heltshe, Sonya L.
    West, Natalie E.
    Skalland, Michelle
    Sanders, Don B.
    Jain, Raksha
    Barto, Tara L.
    Fogarty, Barbra
    Marshall, Bruce C.
    VanDevanter, Donald R.
    Flume, Patrick A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (11) : 1295 - 1305
  • [34] The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation
    Lisa A Carmody
    Jiangchao Zhao
    Linda M Kalikin
    William LeBar
    Richard H Simon
    Arvind Venkataraman
    Thomas M Schmidt
    Zaid Abdo
    Patrick D Schloss
    John J LiPuma
    Microbiome, 3
  • [35] The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation
    Carmody, Lisa A.
    Zhao, Jiangchao
    Kalikin, Linda M.
    LeBar, William
    Simon, Richard H.
    Venkataraman, Arvind
    Schmidt, Thomas M.
    Abdo, Zaid
    Schloss, Patrick D.
    LiPuma, John J.
    MICROBIOME, 2015, 3
  • [36] Profiling of Bacterial and Fungal Microbial Communities in Cystic Fibrosis Sputum Using RNA
    Grahl, Nora
    Dolben, Emily L.
    Filkins, Laura M.
    Crocker, Alex W.
    Willger, Sven D.
    Morrison, Hilary G.
    Sogin, Mitchell L.
    Ashare, Alix
    Gifford, Alex H.
    Jacobs, Nicholas J.
    Schwartzman, Joseph D.
    Hogan, Deborah A.
    MSPHERE, 2018, 3 (04):
  • [37] VIROLOGICAL FINDING IN BRONCHOALVEOLAR LAVAGE (BAL) AMONG NON-TRANSPLANTED CYSTIC FIBROSIS PATIENTS WITH CLINICAL EXACERBATION
    Falk, C.
    Pressler, T.
    Christiansen, C.
    Katzenstein, T. L.
    PEDIATRIC PULMONOLOGY, 2013, 48 : 348 - 348
  • [38] Viral Infection during Pulmonary Exacerbation Correlates with Less Severe Clinical Outcomes in Cystic Fibrosis Pediatric Patients
    Andrzejewska, M.
    Wojsyk-Banaszak, I.
    Jonczyk-Potoczna, K.
    Stachowiak, Z.
    Narozna, B.
    Breborowicz, A.
    Szczepankiewicz, A.
    PEDIATRIC PULMONOLOGY, 2021, 56 : S128 - S128
  • [39] Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis
    McGarry, Meghan E.
    Neuhaus, John M.
    Nielson, Dennis W.
    Burchard, Esteban
    Ly, Ngoc P.
    PEDIATRIC PULMONOLOGY, 2017, 52 (12) : 1550 - 1557
  • [40] Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis
    Regard, Lucile
    Martin, Clemence
    Zemoura, Leila
    Geolier, Virginie
    Sage, Edouard
    Burgel, Pierre-Regis
    JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (08) : 752 - 753